Carmelo Carlo Stella

Laurie Sehn and Carmelo Carlo Stella discuss novel therapies in NHL, focusing on antibody-drug conjugates (ADCs). They talk about the updates on ADCs like brentuximab vedotin, loncastuximab tesirine, and more, and their place in the treatment landscape. Topics include the promising results of Bratuxima of Badoten, comparing a novel therapy with standard treatment, exploring a promising ADC for lymphomas, and the efficacy of pulatuzumab in diffuse large bicell lymphoma treatment.